Corvus Pharmaceuticals, Inc. (CRVS) Misses Q2 EPS by 4c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• JPMorgan Reiterates Overweight Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
• UBS Starts LEAP India Ltd (LEAPIND:IN) at Buy
• JPMorgan Starts NexGen Energy Ltd. (NXE:CN) (NXE) at Overweight